RxDoctor Payments Data

Norman Chang, MD

Internal Medicine · Fredericksburg, VANPI 1629064605

Payments from drug & device makers

$8,247in general payments, 2019–2025

Across 372 payments — averaging $22.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Sanofi-aventis U.S. LLC$730
  • Pfizer$612
  • Novo Nordisk$447
  • AbbVie$429
  • AstraZeneca$401
  • plus $4K from 49 others

What the payments were for

  • Consulting fees$1,42517%
  • Speaking & faculty fees$6908%
  • Food & beverage$6,02673%
  • Education$1061%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,247 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$230,791
Medicare patients
432
Services billed
2,756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin36$58,548
MounjaroTirzepatide38$45,454
EliquisApixaban48$29,066
TrulicityDulaglutide18$26,566
OzempicSemaglutide22$24,850
MyrbetriqMirabegron23$22,363
JanuviaSitagliptin Phosphate14$20,060
LinzessLinaclotide11$9,358
JanumetSitagliptin Phos/Metformin Hcl13$7,203
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide28$2,687
Potassium Chloride51$2,349
Clobetasol Propionate13$1,904
SynthroidLevothyroxine Sodium27$1,816
Olmesartan Medoxomil66$1,711
Nebivolol Hcl27$1,646

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$242$72,02056 claims
Boehringer IngelheimJardiance$181$58,54836 claims
PfizerEliquis$612$29,06648 claims
MerckJanuvia, Janumet$191$27,26327 claims
Novo NordiskOzempic$447$24,85022 claims
Astellas Pharma US IncMyrbetriq$135$22,36323 claims
AbbVieLinzess, Synthroid$429$11,17438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →